Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The **foot-and-mouth disease virus synthetic peptide vaccine** is a veterinary vaccine developed by **Shen Lian Biotech** for the prevention of Foot-and-Mouth Disease (FMD) in livestock, particularly swine and cattle. It represents a significant technological milestone as the first synthetic peptide vaccine for FMD to be commercialized globally. The vaccine is composed of chemically synthesized peptides that mimic the immunodominant epitopes of the Foot-and-Mouth Disease Virus (FMDV) capsid protein, specifically the G-H loop of the VP1 protein. Unlike traditional inactivated vaccines, this synthetic approach eliminates the risk of incomplete virus inactivation or virus escape during the manufacturing process. Furthermore, it allows for the **Differentiation of Infected from Vaccinated Animals (DIVA)**, as the vaccine only contains specific viral peptides rather than the full array of viral proteins. It is approved in China and has been widely utilized in national compulsory immunization programs to control FMD outbreaks.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on foot-and-mouth disease virus synthetic peptide vaccine.